Loading
journalsJournal
Cancer Immunology Research
AACR's tumour immunology journal: mechanisms of immune response and escape, checkpoint and cell-therapy biology and immune biomarkers.
Also called: Cancer Immunol Res
Overview
Cancer Immunology Research (Cancer Immunol Res) is the tumour immunology journal of the American Association for Cancer Research (AACR), appearing monthly since 2013 and published by the society on a hybrid access model. It publishes basic and translational tumour immunology: mechanisms of immune response and escape, T-cell and myeloid biology in the microenvironment, checkpoint and cell-therapy biology, neoantigen and vaccine research and correlative studies from immunotherapy trials. Its readers are tumour immunologists and immunotherapy trialists, and its scope maps to OnCo's Immunotherapy area. It is linked from the biographies of Elizabeth Jaffee, Kellie Smith, Pawel Kalinski, Hatem Soliman and Elizabeth Mittendorf, and a reader would use it for immune biomarkers and mechanisms.
Publisher
American Association for Cancer Research · American Association for Cancer Research
Scope
immunotherapy
Access model
hybrid
Founded
2013
ISSN
2326-6066
Elizabeth A. Mittendorf
Director, Breast Immuno-Oncology Program, Dana-Farber Brigham Cancer Center
Breast surgical oncologyImmunotherapyNeoadjuvant trials
Surgeon-scientist who led IMpassion031 and studies of surgery de-escalation after neoadjuvant immunotherapy.
Elizabeth M. Jaffee
Deputy Director, Sidney Kimmel Comprehensive Cancer Center; Co-Director, Skip Viragh Center for Pancreas Cancer
Pancreatic cancerCancer vaccinesTumour immunology
Pancreatic cancer immunologist who developed the GVAX vaccine and led national cancer policy panels.
Hatem Soliman
Medical Director, Clinical Trials Office; Breast Oncology
Breast cancerImmunotherapyGenomic assays
Hatem Soliman is a breast oncologist leading immunotherapy and genomic-assay trials, including in triple-negative disease.
Kellie N. Smith
Associate Professor of Oncology; Bloomberg~Kimmel Institute
T-cell immunologyNeoantigen-specific T cellsMANAFEST assay
Developed the MANAFEST assay to track the tumour-specific T cells that immunotherapy awakens.
Lei Zheng
Executive Director, Mays Cancer Center, and Vice President for Oncology, UT Health San Antonio
Medical oncologyCancer immunologyCancer centre leadership
Physician-scientist who is Executive Director of the Mays Cancer Center at UT Health San Antonio, the only NCI-designated cancer centre in South Texas.
Pawel Kalinski
Vice Chair for Translational Research, Department of Medicine; Chief, Translational Immuno-Oncology
Dendritic cell vaccinesChemokine modulationTumour microenvironment
Pawel Kalinski is an immunologist reprogramming tumour microenvironments so T cells can enter.
Sang Joon Shin
Professor of Medical Oncology; colorectal cancer and melanoma
Colorectal cancerMelanomaImmunotherapy
Sang Joon Shin is a Yonsei medical oncologist active in colorectal cancer and melanoma immunotherapy trials.
Tasuku Honjo
Immunologist who discovered PD-1 and opened the way to anti-PD-1 therapy
ImmunologyPD-1Checkpoint immunotherapy
He discovered the PD-1 molecule on T cells in 1992 and showed it acts as a brake on immune attack. Blocking it produced nivolumab and pembrolizumab, now used across dozens of cancers; Nobel Prize 2018.
Zelig Eshhar
Immunologist; professor emeritus, Weizmann Institute of Science, latterly Immunology Laboratory, Tel Aviv Sourasky Medical Center
Cancer immunologyChimeric antigen receptorsAdoptive cell therapy
The immunologist who, in 1989, first gave a T cell an antibody's aim. Every CAR-T product on the market descends from that experiment.